Rosiglitazone activation of PPARg suppresses fractalkine signaling

Journal of Molecular Endocrinology

Volumn 44, Issue 2, 2010, Pages 135-142

  Wan, Yihong ^a,b   Evans, Ronald M ^b  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; ENDOTHELIUM CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ACTIVE TRANSPORT; ANIMAL; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CYTOLOGY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; PROTEIN TRANSPORT;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; CELL LINE; CELL MEMBRANE; CELL NUCLEUS; CHEMOKINE CX3CL1; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; MACROPHAGES; MICE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 75749143530     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0090     Document Type: Article

References (21)

1. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA et al. 2006 Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55 1104-1113.
2. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A & Evans RM 1999 PPAR-gamma is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 585-595.
3. Bensinger SJ & Tontonoz P 2008 Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454 470-477.
4. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P & Evans RM 2001a PPAR-gamma dependent and independent effects on macrophagegene expression in lipid metabolism and inflammation. Nature Medicine 7 48-52.
5. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK et al. 2001b A PPAR gamma-LXRABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Molecular Cell 7 161-171.
6. Combadiere C, Feumi C, Raoul W, Keller N, Rodero M, Pezard A, Lavalette S, Houssier M, Jonet L, Picard E et al. 2007 CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. Journal of Clinical Investigation 117 2920-2928.
7. Evans RM, Barish GD & Wang YX 2004 PPARs and the complex journey to obesity. Nature Medicine 10 355-361.
8. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debre P et al. 2000 Rapid progression to AIDS in HIVC individuals with a structural variant of the chemokine receptor CX3CR1. Science 287 2274-2277.
9. Garin A, Pellet P, Deterre P, Debre P & Combadiere C 2002 Cloning and functional characterization of the human fractalkine receptor promoter regions. Biochemical Journal 368 753-760.
10. Hosokawa Y, Nakanishi T, Yamaguchi D, Nakae H & Matsuo T 2005 Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Clinical and Experimental Immunology 139 506-512.
11. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O & Fatatis A 2008 CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Research 68 1715-1722.
12. Keller G, Kennedy M, Papayannopoulou T & Wiles MV 1993 Hematopoietic commitment during embryonic stem cell differentiation in culture. Molecular and Cellular Biology 13 473-486.
13. Lesnik P, Haskell CA & Charo IF 2003 Decreased atherosclerosis in CX3CR1K/K mice reveals a role for fractalkine in atherogenesis. Journal of Clinical Investigation 111 333-340.
14. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD et al. 2003 Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. Journal of Clinical Investigation 111 1241-1250.
15. Moatti D, Faure S, Fumeron F, Amara Mel W, Seknadji P, McDermott DH, Debre P,Aumont MC,Murphy PM, de Prost D et al. 2001 Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97 1925-1928.
16. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T & Miyasaka N 2004 Inhibition of fractalkine ameliorates murine collagen-induced arthritis. Journal of Immunology 173 7010-7016.
17. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, Eagle AR, Vats D, Brombacher F, Ferrante AW et al. 2007 Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447 1116-1120.
18. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG & Glass CK 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 437 759-763.
19. Shah YM, Morimura K & Gonzalez FJ 2007 Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally induced colitis. American Journal of Physiology. Gastrointestinal and Liver Physiology 292 G657-G666.
20. Wan Y, Saghatelian A, Chong LW, Zhang CL, Cravatt BF & Evans RM 2007 Maternal PPAR gamma protects nursing neonates by suppressing the production of inflammatory milk. Genes and Development 21 1895-1908.
21. Willson TM & Wahli W 1997 Peroxisome proliferator-activated receptor agonists. Current Opinion in Chemical Biology 1 235-241.